People who get migraines experience a decreased quality of life - not solely from their migraines, but also from the fear of future migraines, according to the "Life Impact Survey" of almost 4,000 headache sufferers.
People who get migraines experience a decreased quality of life - not solely from their migraines, but also from the fear of future migraines, according to the "Life Impact Survey" of almost 4,000 headache sufferers.
The survey, which was developed in consultation with the National Headache Foundation, was launched in 1999 and data were collected over the next year to evaluate quality-of-life issues facing headache and migraine sufferers, including frequency of headaches, severity of pain and resulting disability.
According to the survey:
•Â Nearly 40% of respondents said they felt anxious or worried about having another severe headache "often" or "all the time." This number rises to 74% when people who said they were "sometimes" anxious or worried about future severe headaches are included.
•Â When asked how much this anxiety and worry bothered them, 47.2% of survey respondents said "a lot" or "a great deal."
•Â Half of the respondents indicated that they felt that family and social activities were limited because of headaches either "often" or "all the time," and another 36% replied that this problem occurred "sometimes."
•Â Three-quarters of respondents replied "yes" or "sometimes" when asked whether they were less likely to socialize because of headaches and whether headaches place stress on relationships with family or friends.
•Â Close to 95% of respondents replied "yes" or "sometimes" when asked whether they avoid being around people when they have a headache. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.